Trials in women

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Women of childbearing age have been viewed as a 'vulnerable population' and have been systematically excluded from early clinical trials. A change in attitude and policies occurred in the last decade, with a consequent increase of women participating in clinical trials. The implications are increasing respect for the woman's capacity to make her own risk-benefit choices, early evaluation of patients that represent the ultimate user of a drug and equal opportunities for women to benefit from the therapeutic potential of new drugs. Drug trials should be designed to identify sex-related effects and to analyse the efficacy and tolerability of antiepileptic drugs (AEDs) by gender. Further aspects should be considered, including changes in response in relation to the menstrual cycle and over the various stages of reproductive life; interactions between hormonal therapies and AEDs; the effect of AEDs on reproductive function and possible consequences of prenatal exposure to AEDs. These considerations become even more critical when pregnant and lactating women are considered, since any risk for the offspring is unacceptable unless drug administration is likely to have major medical benefits for the mother.

Original languageEnglish
Pages (from-to)141-145
Number of pages5
JournalEpilepsy Research
Volume45
Issue number1-3
DOIs
Publication statusPublished - 2001

Fingerprint

Anticonvulsants
Clinical Trials
Pharmaceutical Preparations
Vulnerable Populations
Menstrual Cycle
Drug Users
Pregnant Women
Mothers
Therapeutics

Keywords

  • Antiepileptic drugs
  • Drug trials
  • Ethics
  • Women
  • Women's rights

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Neurology

Cite this

Trials in women. / Battino, Dina.

In: Epilepsy Research, Vol. 45, No. 1-3, 2001, p. 141-145.

Research output: Contribution to journalArticle

Battino, Dina. / Trials in women. In: Epilepsy Research. 2001 ; Vol. 45, No. 1-3. pp. 141-145.
@article{e3150bad87d84330a8ce90b3069fe432,
title = "Trials in women",
abstract = "Women of childbearing age have been viewed as a 'vulnerable population' and have been systematically excluded from early clinical trials. A change in attitude and policies occurred in the last decade, with a consequent increase of women participating in clinical trials. The implications are increasing respect for the woman's capacity to make her own risk-benefit choices, early evaluation of patients that represent the ultimate user of a drug and equal opportunities for women to benefit from the therapeutic potential of new drugs. Drug trials should be designed to identify sex-related effects and to analyse the efficacy and tolerability of antiepileptic drugs (AEDs) by gender. Further aspects should be considered, including changes in response in relation to the menstrual cycle and over the various stages of reproductive life; interactions between hormonal therapies and AEDs; the effect of AEDs on reproductive function and possible consequences of prenatal exposure to AEDs. These considerations become even more critical when pregnant and lactating women are considered, since any risk for the offspring is unacceptable unless drug administration is likely to have major medical benefits for the mother.",
keywords = "Antiepileptic drugs, Drug trials, Ethics, Women, Women's rights",
author = "Dina Battino",
year = "2001",
doi = "10.1016/S0920-1211(01)00240-6",
language = "English",
volume = "45",
pages = "141--145",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Trials in women

AU - Battino, Dina

PY - 2001

Y1 - 2001

N2 - Women of childbearing age have been viewed as a 'vulnerable population' and have been systematically excluded from early clinical trials. A change in attitude and policies occurred in the last decade, with a consequent increase of women participating in clinical trials. The implications are increasing respect for the woman's capacity to make her own risk-benefit choices, early evaluation of patients that represent the ultimate user of a drug and equal opportunities for women to benefit from the therapeutic potential of new drugs. Drug trials should be designed to identify sex-related effects and to analyse the efficacy and tolerability of antiepileptic drugs (AEDs) by gender. Further aspects should be considered, including changes in response in relation to the menstrual cycle and over the various stages of reproductive life; interactions between hormonal therapies and AEDs; the effect of AEDs on reproductive function and possible consequences of prenatal exposure to AEDs. These considerations become even more critical when pregnant and lactating women are considered, since any risk for the offspring is unacceptable unless drug administration is likely to have major medical benefits for the mother.

AB - Women of childbearing age have been viewed as a 'vulnerable population' and have been systematically excluded from early clinical trials. A change in attitude and policies occurred in the last decade, with a consequent increase of women participating in clinical trials. The implications are increasing respect for the woman's capacity to make her own risk-benefit choices, early evaluation of patients that represent the ultimate user of a drug and equal opportunities for women to benefit from the therapeutic potential of new drugs. Drug trials should be designed to identify sex-related effects and to analyse the efficacy and tolerability of antiepileptic drugs (AEDs) by gender. Further aspects should be considered, including changes in response in relation to the menstrual cycle and over the various stages of reproductive life; interactions between hormonal therapies and AEDs; the effect of AEDs on reproductive function and possible consequences of prenatal exposure to AEDs. These considerations become even more critical when pregnant and lactating women are considered, since any risk for the offspring is unacceptable unless drug administration is likely to have major medical benefits for the mother.

KW - Antiepileptic drugs

KW - Drug trials

KW - Ethics

KW - Women

KW - Women's rights

UR - http://www.scopus.com/inward/record.url?scp=0034920099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034920099&partnerID=8YFLogxK

U2 - 10.1016/S0920-1211(01)00240-6

DO - 10.1016/S0920-1211(01)00240-6

M3 - Article

C2 - 11461817

AN - SCOPUS:0034920099

VL - 45

SP - 141

EP - 145

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1-3

ER -